

## **Supplementary File**

### **Appendix 1. Search Strategies**

Searches performed on 26th July 2014. *MeSH (Medical Subject Headings)*

#### **Searched MEDLINE AND Embase using OVID:**

("Deep Sedation"[MeSH] OR "Conscious Sedation"[MeSH] OR "analgesia"[MeSH] OR "Anaesthetics"[MeSH] OR procedural sedation.mp) AND (("Capnography"[MeSH] OR "Carbon Dioxide"[MeSH]) OR ("end AND tidal AND CO2.mp")) AND (("Emergency Medical Services"[MeSH] OR "Emergency Service, Hospital"[MeSH] OR "Trauma Centres"[MeSH] or "Triage"[MeSH]) OR ((Emerg\$))

#### **Scopus**

"sedation" AND "capnography" AND "emergency"

#### **CINAHL**

("Hypnotics and Sedatives" OR "Sedation" OR "Analgesia" OR "Anaesthesia" OR "Conscious Sedation") AND ("Capnography") OR "Carbon Dioxide" OR ("end AND tidal AND CO2.mp") AND "Emergency Medical Services+" OR (MM "Emergency Service+") OR (MM "Physicians, Emergency") OR (MM "Emergencies+") OR "Emergency Patients" OR ((Emerg\$))

#### **Google Scholar**

"procedural sedation" AND "capnography" AND "emergency department" AND "clinical trial"

### **Summary of Search Results**

<b>Database</b>	<b>Articles found from search</b>	<b>Articles remaining after title and abstract review</b>
MEDLINE via OVID	105	21
Embase via OVID	190	18
Scopus	83	17
CINAHL	15	6
Google Scholar	282	31

### **Appendix 2. Risk of Bias Assessment Tools**

#### **Criteria for judging risk of bias in the 'Risk of bias' assessment tool for RCTs<sup>13</sup>**

<b>Potential source of bias</b>	<b>Assessment criteria</b>
<b>Random sequence generation (selection bias)</b>	Criteria for a judgement of 'low risk' of bias: Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random) Criteria for the judgement of 'high risk' of bias: Sequence generated by odd or even date of birth; sequence generated by some rule based on

	<p>date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; allocation by availability of the intervention.</p> <p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information about the sequence generation process to permit judgement of 'Low risk' or 'High risk'.</p>
<b>Allocation concealment (selection bias)</b>	<p>Criteria for a judgement of 'Low risk' of bias: central allocation (including telephone, web-based and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</p> <p>Criteria for the judgement of 'High risk' of bias: Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</p> <p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information to permit judgement of 'Low risk' or 'High risk'.</p>
<b>Blinding of participants and personnel (performance bias due to knowledge of the allocated interventions by participants and personnel)</b>	<p>Criteria for a judgement of 'Low risk' of bias: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</p> <p>Criteria for the judgement of 'High risk' of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</p> <p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information to permit judgement of 'Low risk' or 'High risk'; the study did not address this outcome.</p>
<b>Blinding of outcome data (detection bias due to knowledge of the allocated interventions by outcome assessors)</b>	<p>Criteria for a judgement of 'Low risk' of bias: No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</p> <p>Criteria for the judgement of 'High risk' of bias. No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</p> <p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information to permit judgement of 'Low risk' or 'High risk'; the study did not address this outcome.</p>
<b>Incomplete outcome data (attrition bias)</b>	<p>Criteria for a judgement of 'Low risk' of bias: No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention</p>

	<p>groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</p>
	<p>Criteria for the judgement of 'High risk' of bias: Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; potentially inappropriate application of simple imputation.</p>
	<p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient reporting of attrition/exclusions to permit judgement of 'Low risk' or 'High risk' (e.g. number randomised not stated, no reasons for missing data provided); the study did not address this outcome.</p>
<b>Selective Reporting</b>	<p>Criteria for a judgement of 'Low risk' of bias: The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</p>
	<p>Criteria for the judgement of 'High risk' of bias: Not all of the study's pre-specified primary outcomes have been reported; One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</p>
	<p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information to permit judgement of 'Low risk' or 'High risk'.</p>
<b>Other bias</b>	<p>Criteria for a judgement of 'Low risk' of bias: The study appears to be free of other sources of bias.</p>
	<p>Criteria for the judgement of 'High risk' of bias: For example, the study: Had a potential source of bias related to the specific study design used; or Has been claimed to have been fraudulent; or Had some other problem.</p>
	<p>Criteria for the judgement of 'Unclear risk' of bias: Insufficient information to assess whether an important risk of bias exists; or Insufficient rationale or evidence that an identified problem will introduce bias.</p>

## Criteria for judging risk of bias in the 'Risk of bias' assessment tool for non-randomised studies<sup>14</sup>

Potential source of bias	Assessment criteria
<b>Bias due to confounding</b>	Screening question: Is confounding potentially controllable in the context of this study? 1.1. Did the authors conduct an appropriate analysis that controlled for all the critically important confounding domains? 1.2. If yes to 1.1: Were all of the confounding domains measured validly and reliably by the variables adjusted for in this study? 1.3. Did the authors avoid adjusting for post-intervention variables?
<b>Bias in selection of participants into the study</b>	2.1. Do start of follow-up and start of intervention coincide? 2.2. If no to 2.1: Were adjustment techniques used that are likely to correct for the presence of selection biases?
<b>Bias due to departures from intended interventions</b>	<i>Screening question: Were the intended interventions sufficiently clearly defined and implemented such that a reasonable comparison of them can be made?</i> 3.1. Were the critical co-interventions balanced across intervention groups? 3.2. Were numbers of treatment switches low enough that they do not threaten the validity of the estimated effect of intervention? 3.3. Was implementation failure minor and unlikely to threaten the validity of the outcome estimate? 3.4. If no to 3.1, 3.2 or 3.3: Were adjustment techniques used that were likely to correct for switches, unbalanced co-intervention and implementation failure?
<b>Bias due to missing data</b>	<i>Screening question: Are the intervention groups free of critical differences in participants with missing data?</i> 4.1. Are outcome data reasonably complete? 4.2. Was intervention status reasonably complete for those in whom it was sought? 4.3. Are data reasonably complete for other variables in the analysis? 4.4. If no to 4.1, 4.2 or 4.3: Are the proportion of participants and reasons for missing data similar across interventions? 4.5. If no to 4.1, 4.2 or 4.3: Were appropriate statistical methods used to account for missing data?
<b>Bias in measurement of outcomes or interventions</b>	5.1. Were outcome assessors unaware of the intervention received by study participants? 5.2. Was the outcome measure objective? 5.3. Were the methods of outcome assessment comparable across intervention groups?
<b>Bias in selection of the reported result</b>	6.1. Is it unlikely that the reported effect estimate is available primarily because it was a notable finding among numerous exploratory analyses? 6.2. Is the reported effect estimate unlikely to be prone to selective reporting (on the basis of the results) from among multiple outcome measurements within the outcome domain? 6.3. Is the reported effect estimate unlikely to be prone to selective reporting (on the basis of the results) from among multiple analyses of the outcome measurements? 6.4. Is the reported effect estimate unlikely to be prone to selective reporting (on the basis of the results) from among different subgroups?
<b>Overall bias</b>	Risk of bias judgement

### Appendix 3. Excluded & Included Studies

#### Characteristics of Excluded Studies

Study	Reason for Exclusion
Bassett (2003) <sup>40</sup>	ETCO <sub>2</sub> not recorded
Burton (2006) <sup>41</sup>	Review
Capín (2014) <sup>42</sup>	<50 patients; patients <18yo
Cheuk (2005) <sup>43</sup>	ETCO <sub>2</sub> not recorded
Deitch (2007) <sup>8</sup>	Did not separate adults and children (potentially relevant)

Green (2002) <sup>44</sup>	Review
Hart (1997) <sup>45</sup>	<50 patients; patients <18yo
Kim (2003) <sup>46</sup>	<50 patients; patients <18yo
Karapinar (2006) <sup>47</sup>	ETCO <sub>2</sub> not recorded
Mandt (2012) <sup>48</sup>	ETCO <sub>2</sub> not considered separately
McQuillen (2000) <sup>49</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2003) <sup>50</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2005) <sup>51</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2005) <sup>52</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2007) <sup>53</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2007) <sup>54</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2009) <sup>55</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2010) <sup>56</sup>	No outcome measure related to ETCO <sub>2</sub>
Miner (2013) <sup>57</sup>	ETCO <sub>2</sub> not considered separately
Newstead (2013) <sup>38</sup>	Review
Rahman (2010) <sup>58</sup>	<50 patients; did not specify an abnormal ETCO <sub>2</sub> threshold in relation to adverse event detection
Rahman (2011) <sup>59</sup>	<50 patients
Padmanabhan (2009) <sup>60</sup>	<50 patients (only 6 patients within the ED)
Soleimanpour (2013) <sup>61</sup>	No outcome measure related to ETCO <sub>2</sub>
Soto (2004) <sup>62</sup>	<50 patients; outside the ED
van Loon (2014) <sup>63</sup>	Outside the ED
Waugh (2011) <sup>3</sup>	Review
Weaver (2007) <sup>64</sup>	ETCO <sub>2</sub> not considered separately
Wright (1992) <sup>65</sup>	<50 patients; no ETCO <sub>2</sub> threshold specified
Willman (2007) <sup>66</sup>	ETCO <sub>2</sub> not recorded
Yldzdas (2004) <sup>67</sup>	Outside the ED

### Characteristics of Included Studies

#### Burton et al. (2006)<sup>27</sup>

Methods	<ul style="list-style-type: none"> <li>• Study Design: Prospective Observational</li> <li>• Aim: to determine the ability of ETCO<sub>2</sub> monitoring during PSA to detect acute respiratory events before detection by current monitoring methods.</li> <li>• Duration: May 2004 – October 2004</li> </ul>
Participants	<ul style="list-style-type: none"> <li>• Population: 59 adults and children (≥17y/o, median age 38y/o) undergoing procedural sedation in an ED (60 PSAs); adverse event data was separated according to age</li> <li>• Any Subgroups: none</li> <li>• Location: Maine Medical Center</li> <li>• Inclusion criteria: undergoing propofol sedation in the ED, ≥17y/o</li> <li>• Exclusion criteria: unable to give informed consent</li> <li>• Method of recruitment/any blinding: the treatment team was kept blinded to ETCO<sub>2</sub> levels</li> <li>• Informed consent obtained: prospective informed consent from each patient</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>• Procedure(s) performed: dislocation/fracture reduction, cardioversion, wound closure, transoesophageal echocardiography, tube thoracostomy, disimpaction, foreign body removal</li> <li>• Analgesic/sedative used: propofol, etomidate, midazolam, ketamine (doses not given)</li> <li>• Supplementary oxygen: 2L/minute by cannula</li> <li>• Standard monitoring used: Monitoring continuous oxygen saturation (SpO<sub>2</sub>), heart rate, cardiac rhythm, respiratory rate and interval blood pressure</li> <li>• Equipment used to measure ETCO<sub>2</sub>: LIFEPAK 12 defibrillator/monitor series (Medtronic Emergency Response Systems, Redmond, WA). ETCO<sub>2</sub> monitoring every 30 seconds via a combined oral/nasal cannula for ETCO<sub>2</sub></li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Definition of an adverse event: acute respiratory event: SpO<sub>2</sub> ≤92%; increase in supplemental oxygen provided in response to observed apnoea, hypoventilation, or desaturation; use of bag-valve mask or oral/nasal airway for</li> </ul>

	<p>ventilatory assistance or apnoea; repositioning or airway alignment manoeuvres for ventilation or apnoea; physical or verbal stimulation for depressed ventilation or apnoea; and reversal agent administration; investigational acute respiratory event (abnormal ETCO<sub>2</sub>: change of ≥10mmHg from pre-sedation baseline, ETCO<sub>2</sub> ≤30mmHg, ETCO<sub>2</sub> ≥50mmHg)</p> <ul style="list-style-type: none"> <li>• Reported outcomes: acute respiratory events</li> <li>• Time points reported: time of acute respiratory event, time of clinical recognition</li> </ul>
Summary	<ul style="list-style-type: none"> <li>• Key Conclusions: End-tidal carbon dioxide monitoring of patients undergoing PSA detected many clinically significant acute respiratory events before standard ED monitoring practice did so.</li> <li>• Strengths: Clinicians blinded to capnography.</li> <li>• Weaknesses: not continuous monitoring therefore recording the onset of capnographic and standard monitoring changes was imprecise, study terminated early (ETCO<sub>2</sub> monitoring proceeded in an unblinded fashion, but timing of this is not stated); varying ETCO<sub>2</sub> changes provides a potential for misinterpretation (32/60 had abnormally low ETCO<sub>2</sub>, 5/60 had abnormally high ETCO<sub>2</sub>)</li> </ul>

**Risk of Bias**

	Judgement	Support for Judgement
Confounding	Low risk	Negligible exclusion criteria, supplementary oxygen given to all patients
Participant selection	Low risk	Study size (including power calculation) included, taken from a convenience sample in the ED
Departures from intended interventions	High risk	High risk of attrition bias as the study terminated early, quote: "After review of two 30-patient enrolment blocks, it was determined that further use of ETCO <sub>2</sub> monitoring should proceed in an unblinded fashion and the study was terminated".
Missing Data	Low risk	All participants accounted for with clear exclusion criteria
Measurement of Outcome	Unclear risk	Low risk of performance and detection bias quote: "The clinical team was blinded to study monitoring data, including ETCO <sub>2</sub> findings, throughout the PSA period". But no blinding of outcome assessment: clinicians were aware of the purpose of the study
Selection of the Reported Result	Low risk	All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.
Notes	Study was approved by the institutional review board for research on human subjects, but no information regarding funding/conflict of interest	

**Downs and Black Study Quality Score**

Reporting	External Validity	Interval Validity – Bias	Internal Validity – Confounding	Power	Total
8/11	2/3	6/7	2/6	0/5	18/32

**Deitch et al. (2008)<sup>28</sup>**

Methods	<ul style="list-style-type: none"> <li>• Study Design: RCT</li> <li>• Aim: to determine whether physicians blinded to capnographic data are able to recognise respiratory depression during procedural sedation</li> <li>• Duration: November 2005 - October 2006</li> </ul>
Participants	<ul style="list-style-type: none"> <li>• Population: 110 adults (&gt;18y/o; median age: 37y/o)</li> <li>• Any Subgroups: patients receiving supplementary oxygen vs. compressed air</li> <li>• Location: Albert Einstein Medical Center, Philadelphia</li> <li>• Inclusion criteria: undergoing propofol sedation in the ED, &gt;18y/o</li> <li>• Exclusion criteria: severe chronic obstructive pulmonary disease; chronic oxygen requirements; haemodynamic instability; respiratory distress; pregnancy; inability to provide informed consent; allergy to study drugs</li> <li>• Method of recruitment/any blinding: the treatment team was kept blinded to ETCO<sub>2</sub> levels</li> <li>• Informed consent obtained: written informed consent from each patient</li> </ul>

Interventions	<ul style="list-style-type: none"> <li>• Procedure(s) performed: abscess drainage or fracture/joint reduction</li> <li>• Analgesic/sedative used: 1-1.5mg/kg IV propofol with additional 0.5mg/kg boluses until the desired level of sedation was achieved</li> <li>• Supplementary oxygen: 3/L minute by cannula (56/110 patients)</li> <li>• Standard Monitoring used: pulse oximetry, pulse rate, blood pressure</li> <li>• Equipment used to measure ETCO<sub>2</sub>: NPB-Microstream 75 ETCO<sub>2</sub> monitor (Nellcor Puritan Bennett Inc., Pleasanton, CA) connected to a nasal cannula (continuous sampling)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Definition of an adverse event: Hypoxia (SpO<sub>2</sub> &lt;93% for &gt;15 seconds); Respiratory depression (ETCO<sub>2</sub> ≥50mmHg, ≥10% increase or decrease from baseline, loss of waveform); Hypotension; Bradycardia; Vomiting; Prolonged ED stay (&gt;2 hours after the procedure); Admission</li> <li>• Reported outcomes: hypoxia, respiratory depression</li> <li>• Time points reported: time from first dose of medication to return to baseline alertness</li> </ul>
Summary	<ul style="list-style-type: none"> <li>• Key Conclusions: Blinded capnography frequently identified respiratory depression undetected by the treating physicians</li> <li>• Strengths: Clinicians blinded to capnography, eligible patients were entered into trial consecutively 24 hours per day; continuous sampling</li> <li>• Weaknesses: Investigation of the use of capnography was not the primary aim, the capnography monitor did not provide exact intervals between ETCO<sub>2</sub> changes and the onset of hypoxia</li> </ul>

<b>Risk of Bias</b>		
	<b>Judgement</b>	<b>Support for Judgement</b>
Confounding	Low risk	Supplementary oxygen was given to 56/110 patients but these patients were analysed separately
Participant selection	Low risk	All patients undergoing propofol sedation in the ED (aged >18y/o) could be included
Departures from intended interventions	Low risk	None
Missing Data	Low risk	All participants accounted for with clear exclusion criteria
Measurement of Outcome	Low risk	Low risk of performance and detection bias: blinding of personnel - quote: "the treatment team was kept blinded to ETCO <sub>2</sub> levels" blinding of the outcome assessment: "The treatment team was unaware that the research associates were evaluating their (i.e., the treatment team's) ability to recognise respiratory depression with standard PSA monitoring."
Selection of the Reported Result	Low risk	All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way, detailed statistical tests listed.
Notes	Study was approved by the institutional review board, but no information regarding funding/conflict of interest	

#### **Downs and Black Study Quality Score**

<b>Reporting</b>	<b>External Validity</b>	<b>Interval Validity – Bias</b>	<b>Internal Validity – Confounding</b>	<b>Power</b>	<b>Total</b>
10/11	2/3	6/7	3/6	5/5	25/32

#### **Deitch et al. (2010)<sup>26</sup>**

Methods	<ul style="list-style-type: none"> <li>• Study Design: RCT</li> <li>• Aim: to determine whether the use of real-time capnography is associated with a 15% decrease in the incidence of hypoxia compared with standard monitoring alone during ED procedural sedation with propofol</li> <li>• Duration: November 2006 – February 2008</li> </ul>
Participants	<ul style="list-style-type: none"> <li>• Population: 132 adults (&gt;18y/o; median age: 34y/o)</li> <li>• Any Subgroups: none</li> <li>• Location: Albert Einstein Medical Center, Philadelphia</li> <li>• Inclusion criteria: undergoing propofol sedation in the ED</li> <li>• Exclusion criteria: severe chronic obstructive pulmonary disease; chronic oxygen requirements; haemodynamic instability; respiratory distress; pregnancy; inability to provide informed consent; allergy to propofol, morphine</li> </ul>

	<ul style="list-style-type: none"> <li>or fentanyl</li> <li>Method of recruitment/any blinding: computer-generated randomisation list, blinded capnography</li> <li>Informed consent obtained: yes (inability to consent was an exclusion criteria)</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>Procedure(s) performed: abscess incision and drainage; fracture/joint reduction</li> <li>Analgesic/sedative used: 0.05mg/kg morphine or 0.5µg/kg fentanyl IV for analgesia for at least 30 minutes then 1mg/kg propofol with additional 0.5mg/kg boluses until the desired level of sedation was achieved</li> <li>Supplementary oxygen: 3/L minute by cannula</li> <li>Standard Monitoring used: pulse oximetry, pulse rate, blood pressure</li> <li>Equipment used to measure ETCO<sub>2</sub>: Capnostream 20 monitor (Oridion Medical, Needham, MA) using a nasal-oral CO<sub>2</sub> cannula (data recorded every 5 seconds)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>Definition of an adverse event: Hypoxia (SpO<sub>2</sub> &lt;93% for &gt;15 seconds); Respiratory depression (ETCO<sub>2</sub> ≥50mmHg, ≥10% increase or decrease from baseline, loss of waveform ≥15 sec); Hypotension; Bradycardia; Arrhythmia; Vomiting; Prolonged ED stay; Admission</li> <li>Reported outcomes: hypoxia, respiratory depression</li> <li>Time points reported: time from capnographic evidence of respiratory depression to hypoxia</li> </ul>
Summary	<ul style="list-style-type: none"> <li>Key Conclusions: Capnography can provide early warning of ventilatory abnormalities, alerting physicians to respiratory depression before the onset of a hypoxic event.</li> <li>Strengths: Only RCT to include a control (i.e. patients randomised to capnography or blinded capnography)</li> <li>Weaknesses: Underpowered: required 72 pts in each arm for 80% power; High rate of hypoxia → a smaller rate (consistent with other studies) may explain why difference between groups was not statistically significant; Capnostream 20 records every 5 seconds (standard monitoring e.g. blood pressure occurred at unspecified spaced intervals; the frequency of monitoring is a confounding factor); clinicians aware of which group they were allocated to; stringent set of criteria for respiratory depression meant higher rate of physician intervention for respiratory depression (in the unblinded group). Fewer physician interventions in this group may have decreased the recorded difference in the rate of hypoxia between the two groups.</li> </ul>

<b>Risk of Bias</b>		
	<b>Judgement</b>	<b>Support for Judgement</b>
Random sequence generation ( <i>Selection bias</i> )	Low risk	Quote: "Patients were randomly assigned... by research associates using a computer-generated randomisation list"
Allocation concealment ( <i>Selection bias</i> )	Low risk	Quote: "Research associates and treating physicians were blinded to the randomisation choice until after enrolment"
Blinding of participants and personnel ( <i>Performance and detection bias</i> )	High risk	Clinicians were aware of which group they were allocated to
Blinding of outcome assessment ( <i>Detection bias</i> )	Moderate risk	No blinding of outcome assessment
Incomplete outcome data ( <i>Attrition bias</i> )	Low risk	No missing outcome data
Selective outcome reporting ( <i>Reporting bias</i> )	Low risk	All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way
Other bias	Low risk	The study appears to be free of other sources of bias.

### Downs and Black Study Quality Score

Reporting	External Validity	Interval Validity – Bias	Internal Validity – Confounding	Power	Total
10/11	2/3	6/7	6/6	5/5	28/32

### Deitch et al. (2011)<sup>29</sup>

Methods	<ul style="list-style-type: none"> <li>• Study Design: RCT</li> <li>• Aim: to compare the frequencies of subclinical respiratory depression and other adverse events.</li> <li>• Duration: January 2009 – November 2010</li> </ul>
Participants	<ul style="list-style-type: none"> <li>• Population: 117 adults (&gt;18y/o; mean age: 34.5y/o)</li> <li>• Any Subgroups: high-flow oxygen or room air (both 15L/min)</li> <li>• Location: Albert Einstein Medical Center, Philadelphia</li> <li>• Inclusion criteria: undergoing propofol sedation in the ED</li> <li>• Exclusion criteria: severe chronic obstructive pulmonary disease; chronic oxygen requirements; haemodynamic instability; respiratory distress; pregnancy; inability to provide informed consent; allergy to propofol, morphine or fentanyl</li> <li>• Method of recruitment/any blinding: all subjects received capnography, no blinding of capnography</li> <li>• Informed consent obtained: yes (inability to consent was an exclusion criteria)</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>• Procedure(s) performed: abscess incision and drainage; fracture/joint reduction</li> <li>• Analgesic/sedative used: 1mg/kg propofol with additional 0.5mg/kg boluses until the desired level of sedation was achieved</li> <li>• Supplementary oxygen: 15L/min (59/117)</li> <li>• Standard Monitoring used: pulse oximetry, pulse rate, blood pressure</li> <li>• Equipment used to measure ETCO<sub>2</sub>: Capnostream 20 monitor (Oridion Medical, Needham, MA) using a nasal-oral CO<sub>2</sub> cannula (data recorded every 5 seconds)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Definition of an adverse event: Hypoxia (SpO<sub>2</sub> &lt;93% for ≥15 seconds); Respiratory depression (ETCO<sub>2</sub> ≥50mmHg, ≥10% increase or decrease from baseline, loss of waveform ≥15 sec); Hypotension; Bradycardia; Arrhythmia; Vomiting; Prolonged ED stay; Admission</li> <li>• Reported outcomes: hypoxia, respiratory depression</li> <li>• Time points reported: time from initial propofol administration until the patient returned to baseline alertness, time of intervention</li> </ul>
Summary	<ul style="list-style-type: none"> <li>• Key Conclusions: Capnography can provide early warning of ventilatory abnormalities, alerting physicians to respiratory depression before the onset of a hypoxic event.</li> <li>• Strengths: comprehensive exclusion criteria, patients randomised to high-flow oxygen or room air and statistical analyses between the two groups were performed</li> <li>• Weaknesses: Underpowered: defined hypoxia as SpO<sub>2</sub> &lt;93% whereas we believe using the common threshold of 90% would have decreased the incidence of hypoxia; Capnostream 20 records every 5 seconds (standard monitoring e.g. blood pressure occurred at unspecified spaced intervals; the frequency of monitoring is a confounding factor); clinicians aware of which group they were allocated to</li> </ul>

### Risk of Bias

	Judgement	Support for Judgement
Confounding	Low risk	Comprehensive exclusion criteria, patients randomised to high-flow oxygen or room air and statistical analyses between the two groups were performed
Participant selection	Low risk	Undergoing propofol sedation in the ED
Departures from intended interventions	Low risk	None
Missing Data	Low risk	All participants accounted for
Measurement of Outcome	High risk	Performance and detection bias: blinding of personnel - quote: "We believe that the improved safety real-time capnography provides should

		be part of routine practice, and thus it would not be ethical to blind our clinicians” blinding of the outcome assessment: clinicians were aware that capnography was included as an outcome assessment
Selection of the Reported Result	Low risk	Key results with reference to study objectives summarised. All of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way
Notes	Study was approved by the institutional review board, but no information regarding funding/conflict of interest	

**Downs and Black Study Quality Score**

Reporting	External Validity	Interval Validity – Bias	Internal Validity – Confounding	Power	Total
10/11	2/3	4/7	3/6	5/5	24/32

**Miner et al. (2002)<sup>30</sup>**

Methods	<ul style="list-style-type: none"> <li>Study Design: Prospective Observational</li> <li>Aim: to evaluate the utility of ETCO<sub>2</sub> monitors to detect RD in patients undergoing procedural sedation</li> <li>Duration: December 2000 – April 2001</li> </ul>
Participants	<ul style="list-style-type: none"> <li>Population: 74 adults (mean age: 37.6 y/o)</li> <li>Any Subgroups: none</li> <li>Location: an urban county medical centre</li> <li>Inclusion criteria: adult ED patients who were monitored during procedural sedation as per ED standard guidelines</li> <li>Exclusion criteria: inability to give consent</li> <li>Method of recruitment/any blinding: no blinding</li> <li>Informed consent obtained: given (method not stated)</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>Procedure(s) performed: fracture reduction, dislocation reduction, incision and drainage of abscess, thoracostomy tube placement, hernia reduction, cardioversion, complex laceration repair</li> <li>Analgesic/sedative used: methohexital/propofol/etomidate or fentanyl and midazolam.</li> <li>Supplementary oxygen: 47/74 (dose not stated)</li> <li>Standard monitoring used: Pulse oximetry, heart rate, blood pressure, respiratory rate, ETCO<sub>2</sub> every 2 minutes + modified version of the *Observer's Assessment of Alertness/Sedation Scale (OAA/S)</li> <li>Equipment used to measure ETCO<sub>2</sub>: nasal cannula with portable Capnocheck II (BCI, Waukesha, WI)</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>Definition of an adverse event: Respiratory depression (oxygen saturation of &lt;90% for ≥1 minute; ETCO<sub>2</sub> &gt;50 mm Hg; absent ETCO<sub>2</sub> waveform; ETCO<sub>2</sub> change from baseline &gt;10 mm Hg).</li> <li>Reported outcomes: Respiratory depression</li> <li>Time points reported: duration of assisted ventilation</li> </ul>
Summary	<ul style="list-style-type: none"> <li>Key Conclusions: The ETCO<sub>2</sub> monitor detected patients who met our criteria for RD who were not detected by pulse oximetry.</li> <li>Strengths: detailed statistics</li> <li>Weaknesses: no blinding, the rates of RD between different drugs was significantly different but the number of patients meeting criteria for respiratory depression was not separated according to sedation used, ETCO<sub>2</sub> monitoring every 2 minutes, unclear exclusion criteria</li> </ul>

**Risk of Bias**

	Judgement	Support for Judgement
Confounding	High risk	Liberal exclusion criteria, duration of sedation & monitoring not given, 47 patients received supplementary oxygen as part of airway management but they were not considered separately
Participant selection	Low risk	Adult ED patients who were monitored during procedural sedation as per ED standard guidelines
Departures from intended interventions	Low risk	None
Missing Data	Unclear risk	All participants accounted for but reasons for the 2 unsuccessful

		procedures were not given
Measurement of Outcome	Low risk	No blinding
Selection of the Reported Result	Low risk	Key results with reference to study objectives summarised. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way
Notes	Study was approved by The Institutional Review Board (IRB) of Hennepin County Medical Center review board but no information regarding funding	

**Downs and Black Study Quality Score**

Reporting	External Validity	Interval Validity – Bias	Internal Validity – Confounding	Power	Total
9/11	2/3	3/7	3/6	5/5	24/32

**Miner (2003)<sup>31</sup>**

Methods	<ul style="list-style-type: none"> <li>Study Design: Prospective Observational</li> <li>Aim: to determine whether there is a correlation between the achieved levels of sedation by the BIS score with the rate of RD as measured by ETCO<sub>2</sub> and pulse oximetry</li> <li>Duration: April 2001 – June 2001</li> </ul>
Participants	<ul style="list-style-type: none"> <li>Population: 108 adults (&gt;18y/o, mean age: 40.9y/o)</li> <li>Any Subgroups: none</li> <li>Location: an urban county medical centre ED</li> <li>Inclusion criteria: not stated</li> <li>Exclusion criteria: inability to give consent</li> <li>Method of recruitment/any blinding: blinded to the BIS monitor only</li> <li>Informed consent obtained: given (method not stated)</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>Procedure(s) performed: fracture reduction, dislocation reduction, incision and drainage of abscess, thoracostomy tube placement, complex laceration repair</li> <li>Analgesic/sedative used: methohexital/propofol/etomidate or fentanyl and midazolam.</li> <li>Supplementary oxygen: 87/108 (dose not stated)</li> <li>Standard monitoring used: Pulse oximetry, heart rate, blood pressure, ETCO<sub>2</sub> continuously. Bispectral electroencephalographic (EEG) – BIS monitor</li> <li>Equipment used to measure ETCO<sub>2</sub>: nasal-sample, equipment not stated</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>Definition of an adverse event: Respiratory depression (oxygen saturation of &lt;90%; ETCO<sub>2</sub> change from baseline &gt;10 mm Hg; absent ETCO<sub>2</sub> waveform); vomiting; aspiration; intubation; transfer to higher level of care after the procedure; assisted ventilation; pain</li> <li>Reported outcomes: Respiratory depression</li> <li>Time points reported: duration of assisted ventilation</li> </ul>
Summary	<ul style="list-style-type: none"> <li>Key Conclusions: The ETCO<sub>2</sub> monitor detected patients who met our criteria for RD who were not detected by pulse oximetry.</li> <li>Strengths: detailed statistics including power analysis</li> <li>Weaknesses: no blinding, small patient numbers (convenience sample), study finished early, did not include the patient's state of health (such as ASA scores) or a pre- procedure airway assessment in analysis; change in baseline of &gt;10mmHg ETCO<sub>2</sub> is not very strict criteria</li> </ul>

**Risk of Bias**

	Judgement	Support for Judgement
Confounding	Low risk	Compared rates of RD between different sedating agents; duration of sedation & monitoring not given
Participant selection	Unclear risk	Inclusion criteria not strictly specified
Departures from intended interventions	Low risk	None
Missing Data	Unclear risk	All participants accounted for but reasons for the 3 unsuccessful procedures were not given
Measurement of Outcome	High risk	No blinding of capnography

Selection of the Reported Result	Low risk	Key results with reference to study objectives summarised. All of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way
Notes	Study was approved by The Institutional Review Board (IRB) of Hennepin County Medical Center review board but no information regarding funding	

**Downs and Black Study Quality Score**

Reporting	External Validity	Interval Validity – Bias	Internal Validity – Confounding	Power	Total
10/11	2/3	5/7	4/6	5/5	26/32

**Sivilotti (2010)<sup>6</sup>**

Methods	<ul style="list-style-type: none"> <li>• Study Design: RCT</li> <li>• Aim: to determine which monitor would first detect a respiratory event: the pulse oximeter or the capnometer</li> <li>• Duration: December 2004 – February 2006</li> </ul>
Participants	<ul style="list-style-type: none"> <li>• Population: 63 adults (21-57y/o, mean age: 39y/o)</li> <li>• Any Subgroups: random assignment to groups receiving ketamine or fentanyl</li> <li>• Location: a university-affiliated tertiary care hospital</li> <li>• Inclusion criteria: Class I or II patients (ASA)</li> <li>• Exclusion criteria: Significant active cardiac, pulmonary, hepatic or renal disease, recent substance abuse, prior/current opioid dependence, OSA, prior psychosis, allergy to ketamine, fentanyl or propofol, weighed &gt;130kg, acutely intoxicated</li> <li>• Method of recruitment/any blinding: none mentioned</li> <li>• Informed consent obtained: written informed consent</li> </ul>
Interventions	<ul style="list-style-type: none"> <li>• Procedure(s) performed: fracture reduction or incision and drainage of abscess</li> <li>• Analgesic/sedative used: 0.3mg/kg ketamine or 1.5µg/kg fentanyl IV then 0.4mg/kg propofol IV 2 minutes later then 0.1mg/kg boluses every 30 seconds</li> <li>• Supplementary oxygen: administered if patients developed oxygen desaturation (number of patients &amp; dose not stated)</li> <li>• Standard monitoring used: Continuous pulse oximetry, ECG and blood pressure</li> <li>• Equipment used to measure ETCO<sub>2</sub>: Nellcor Smart CapnoLine O<sub>2</sub>/CO<sub>2</sub> Oral Nasal Cannula (Tyco Healthcare), continuous sampling</li> </ul>
Outcomes	<ul style="list-style-type: none"> <li>• Definition of an adverse event: Hypoventilation (ETCO<sub>2</sub> &gt; 50mmHg or a rise or fall of &gt;10mmHg from pre-sedation baseline or loss of waveform for &gt;30 seconds or recurrent losses of waveform); Oxygen desaturation (pulse oximetry &lt;92%)</li> <li>• Reported outcomes: hypoventilation, oxygen desaturation</li> <li>• Time points reported: time of an adverse event</li> </ul>
Summary	<ul style="list-style-type: none"> <li>• Key Conclusions: During PSA in adults breathing room air, desaturation detectable by pulse oximeter usually occurs before overt changes in capnometry are identified</li> <li>• Strengths: formed part of a prospective clinical trial thus there was consistent drug titration with only a small number of trained study physicians performing sedations and collecting data, and independent validation of clinician observations with the monitor's automatic data recording; included the patient's state of health (ASA score)</li> <li>• Weaknesses: No a priori null hypothesis tested, substantial variability among and within participants in capnometry at baseline, physicians failed to recognise a 10mmHg rise in ETCO<sub>2</sub>, capnometric abnormalities were poorly sensitive/late findings in patients with hypoxia on room air; considerable breath to breath variability, use of capnography was not the primary research question; study terminated early (safety in favour of ketamine); not blinded to capnography; did not specify the level of sedation achieved</li> </ul>

**Risk of Bias**

	Judgement	Support for Judgement
Confounding	High risk	Consistent drug titration, trained personnel; liberal exclusion criteria; depth of sedation, duration of sedation and duration of monitoring not given. Supplementary oxygen: administered if patients developed oxygen desaturation (number of patients & dose not stated and not included in analysis)
Participant	Low risk	Class I or II patients (ASA)

selection		
Departures from intended interventions	Low risk	None
Missing Data	High risk	Incomplete outcome data “The primary trial was stopped by the data monitoring committee following a planned interim analysis at 50% enrolment when an important difference in safety emerged in favour of ketamine.”
Measurement of Outcome	High risk	No blinding of outcome assessment ( <i>Detection bias</i> ), clinicians were aware that capnography was included as an outcome assessment, quote: “no a priori null hypothesis [related to capnography] tested”, bias against the use of capnography
Selection of the Reported Result	Unclear risk	Reported in the pre-specified way but difficult to analyse given the early termination of the trial
Notes	Study was approved by The Institutional Review Board (IRB) of Hennepin County Medical Center review board but no information regarding funding	

***Downs and Black Study Quality Score***


<b>Reporting</b>	<b>External Validity</b>	<b>Interval Validity – Bias</b>	<b>Internal Validity – Confounding</b>	<b>Power</b>	<b>Total</b>
9/11	2/3	4/7	3/6	0/5	18/32

**A**

	Confounding	Participant Selection	Departure from Intended Interventions	Missing Data	Outcome Measurement	Selection of Reported Results
Burton 2006	+	+	-	+	?	+
Deitch 2008	+	+	+	+	+	+
Deitch 2011	+	+	+	+	-	+
Miner 2002	-	+	+	?	+	+
Miner 2003	+	?	+	?	-	+
Sivilotti 2010	-	+	+	-	-	?

+ Low Risk of bias   
 ? Unclear Risk of Bias   
 - High Risk of Bias

**B**



**Appendix 4.** Risk of bias graphs. **A:** Review author's (CD) judgements about each risk of bias item according to the Cochrane risk of bias tool. **B:** Review author's judgements about each risk of bias item presented as percentages across all included studies. N.b. the RCT that included capnography as a primary intervention was judged separately and is summarised in Appendix 3.

## Appendix 5. Summary of Findings Table

Outcomes	Illustrative Comparative Risk*		Relative Effect (Random-effects model, 95% CI)	Heterogeneity: I <sup>2</sup> (95% CI; p-value)	No. of Participants (studies)	Quality of the Evidence (GRADE)	Comments
	TP x TN (173 x 417)	FP x FN (218 x 65)					
Diagnostic Accuracy of Capnography	TP x TN (173 x 417)	FP x FN (218 x 65)	Odds Ratio: 5.87 (2.41-14.3)	66.88% (26.18-85.14; 0.006)	662 (7)	⊕⊕⊕○ Moderate <sup>1</sup>	Low false negative rate, Large OR, Moderate heterogeneity; Average Downs and Black score: 23.29 (moderate quality)
Detection of Adverse Events before Standard Monitoring	154/318 (Adverse events detected solely by ETCO <sub>2</sub> /Total Adverse Events)		48.82% (32.85-64.92)	52.14% (78.73-93.78; 0.0491)	662 (7)	⊕⊕○○ Low <sup>1,2</sup>	High risk of bias; lack of blinding; Average Downs and Black score: 23.29 (moderate quality)

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

\***Illustrative comparative risks** are typical risks of the outcome occurring without the intervention (assumed risks) and the corresponding risks of the outcome occurring with the intervention. TP (True Positive); TN (True Negative); FP (False Positive); FN (False Negative)

1. Less than ten studies, so creating a funnel plot was not applicable

2. Confidence interval includes zero (no difference)

## Appendix 5. Summary of Findings Table

Outcomes	Illustrative Comparative Risk*		Relative Effect (Random-effects model, 95% CI)	Heterogeneity: I <sup>2</sup> (95% CI; p-value)	No. of Participants (studies)	Quality of the Evidence (GRADE)	Comments
	TP x TN (173 x 417)	FP x FN (218 x 65)					
Diagnostic Accuracy of Capnography	TP x TN (173 x 417)	FP x FN (218 x 65)	Odds Ratio: 5.87 (2.41-14.3)	66.88% (26.18-85.14; 0.006)	662 (7)	⊕⊕⊕○ Moderate <sup>1</sup>	Low false negative rate, Large OR, Moderate heterogeneity; Average Downs and Black score: 23.29 (moderate quality)
Detection of Adverse Events before Standard Monitoring	154/318 (Adverse events detected solely by ETCO <sub>2</sub> /Total Adverse Events)		48.82% (32.85-64.92)	52.14% (78.73-93.78; 0.0491)	662 (7)	⊕⊕○○ Low <sup>1,2</sup>	High risk of bias; lack of blinding; Average Downs and Black score: 23.29 (moderate quality)

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

\***Illustrative comparative risks** are typical risks of the outcome occurring without the intervention (assumed risks) and the corresponding risks of the outcome occurring with the intervention. TP (True Positive); TN (True Negative); FP (False Positive); FN (False Negative)

1. Less than ten studies, so creating a funnel plot was not applicable

2. Confidence interval includes zero (no difference)

## **References (numbers 1-39 in the main text, 40-67 in the supplementary file)**

1. Jagoda AS, Campbell M, Karas S, et al. Clinical Policy for Procedural Sedation and Analgesia in the Emergency Department. *Ann Emerg Med.* 1998;31(5):663–677.
2. Medicine E, Party W, Management A. Safe Sedation of Adults in the Emergency. 2012;(November).
3. Waugh JB, Epps C, Khodneva Y. Capnography enhances surveillance of respiratory events during procedural sedation: a meta-analysis. *J Clin Anesth.* 2011;23(3):189–96.
4. Godwin SA, Burton JH, Gerardo CJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. *Ann Emerg Med.* 2014;63(2):247–58.e18.
5. Hoffman GM, Nowakowski R, Troshynski TJ, Berens RJ, Weisman SJ. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. *Pediatrics.* 2002;109(2):236–43.
6. Sivilotti MLA, Messenger DW, van Vlymen J, Dungey PE, Murray HE. A comparative evaluation of capnometry versus pulse oximetry during procedural sedation and analgesia on room air. *CJEM.* 2010;12(5):397–404.
7. Krauss B, Hess DR. Capnography for procedural sedation and analgesia in the emergency department. *Ann Emerg Med.* 2007;50(2):172–81.
8. Deitch K, Chudnofsky CR, Dominici P. The utility of supplemental oxygen during emergency department procedural sedation and analgesia with midazolam and fentanyl: a randomized, controlled trial. *Ann Emerg Med.* 2007;49(1):1–8.
9. Green SM, Krauss B. Propofol in emergency medicine: pushing the sedation frontier. *Ann Emerg Med.* 2003;42:792–97.
10. Moher D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *Ann Intern Med.* 2009;151(4):264.
11. Medical Subject Headings (MeSH) MeSH Descriptor Data. Tree Number: E01.370.386.700.150. National Library of Medicine 2014. Retrieved 27/07/2014. *MeSH.*
12. Cochrane Wounds Group, Cochrane Data Extraction Sheet. Available at: [<http://wounds.cochrane.org/forms-authors>] Accessed 06/08/2014
13. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343(oct18\_2):d5928.
14. Sterne J, Higgins J, Reeves B, et al. Extending the Cochrane Risk of Bias tool to assess risk of bias in non-randomized studies. 2013;(September):1–32.
15. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health.* 1998;52(6):377–84.
16. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;336(7650):924–6.

17. MedCalc for Mac, version 13.3.3 (MedCalc Software, Ostend, Belgium).
18. Manetti N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst.* 1959;22(4):719–48.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials.* 1986;7(3):177–188.
20. Fischer JE, Bachmann LM, Jaeschke R: A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. *Intensive Care Med* 2003, 29:1043-1051
21. Meta-DiSc: A software for meta-analysis of test accuracy data. *BMC Medical Research Methodology.* 2006, 6:31.
22. Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. *Ann Math Stat.* 1950;21(4):607–611.
23. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I<sup>2</sup> index? *Psychol Methods.* 2006;11(2):193–206.
24. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327(7414):557–60.
25. Glasziou P, Irwig L, Bain C, Colditz G: Systematic Reviews in Healthcare: a Practical Guide. Cambridge: Cambridge University Press; 2001.
26. Deitch K, Miner J, Chudnofsky CR, Dominici P, Latta D. Does end tidal CO<sub>2</sub> monitoring during emergency department procedural sedation and analgesia with propofol decrease the incidence of hypoxic events? A randomized, controlled trial. *Ann Emerg Med.* 2010;55(3):258–64.
27. Burton JH, Harrah JD, Germann CA, Dillon DC. Does end-tidal carbon dioxide monitoring detect respiratory events prior to current sedation monitoring practices? *Acad Emerg Med.* 2006;13(5):500–4.
28. Deitch K, Chudnofsky CR, Dominici P. The utility of supplemental oxygen during emergency department procedural sedation with propofol: a randomized, controlled trial. *Ann Emerg Med.* 2008;52(1):1–8.
29. Deitch K, Chudnofsky CR, Dominici P, Latta D, Salamanca Y. The utility of high-flow oxygen during emergency department procedural sedation and analgesia with propofol: a randomized, controlled trial. *Ann Emerg Med.* 2011;58(4):360–364.e3.
30. Miner JR, Heegaard W, Plummer D. End-tidal carbon dioxide monitoring during procedural sedation. *Acad Emerg Med.* 2002;9(4):275–80.
31. Miner JR, Biros MH, Heegaard W, Plummer D. Bispectral electroencephalographic analysis of patients undergoing procedural sedation in the emergency department. *Acad Emerg Med.* 2003;10(6):638–43.
32. Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. *The Clinical Biochemist Review.* 2008;29:S83 - S87.

33. Katz DL, Elmore JG, Wild DM, Lucan SC. *Jekel's Epidemiology, Biostatistics, Preventive Medicine and Public Health*. 4th ed Elsevier Saunders; 2014.
34. Beitz A, Riphaut A, Meining A, et al. Capnographic monitoring reduces the incidence of arterial oxygen desaturation and hypoxemia during propofol sedation for colonoscopy: a randomized, controlled study (ColoCap Study). *Am J Gastroenterol*. 2012;107(8):1205–12
35. Gagnier JJ, Morgenstern H, Altman DG, Berlin J, Chang S, McCulloch P, et al. Consensus-based recommendations for investigating clinical heterogeneity in systematic reviews. *BMC Med Res Methodol* 2013;13:106.
36. Green SM, Pershad J. Should capnographic monitoring be standard practice during emergency department procedural sedation and analgesia? Pro and con. *Ann Emerg Med*. 2010;55(3):265–7.
37. Mason KP, Mason KP, Green SM, Piacevoli Q. Adverse event reporting tool to standardize the reporting and tracking of adverse events during procedural sedation: a consensus document from the World SIVA International Sedation Task Force. *Br J Anaesth*. 2012;108(1):13–20.
38. Newstead B, Bradburn S, Appelboam A, et al. Propofol for adult procedural sedation in a UK emergency department: safety profile in 1008 cases. *Br J Anaesth*. 2013;111(4):651–5.
39. Kidd LR, Lyons SC, Lloyd G. Paediatric procedural sedation using ketamine in a UK emergency department: a 7 year review of practice. *Br J Anaesth*. 2016; 116 (4): 518–23.
40. Bassett K, Anderson JL, Pribble CG, Guenther E. Propofol for Procedural Sedation in Children in the Emergency Department. 2003;(December). doi:10.1016/mem.2003.368.
41. Burton JH, Miner JR, Shipley ER, Strout TD, Becker C, Thode HC. Propofol for emergency department procedural sedation and analgesia: a tale of three centers. *Acad Emerg Med*. 2006;13(1):24–30.
42. Capín AM, Navarro CM, López RL, Mara R. Utilidad de la capnografía en la monitorización durante procedimientos de sedoanalgesia . Influencia de la administración de oxígeno en los parámetros monitorizados. *An Pediatry (Barc)*. 2014;80(1).
43. Cheuk DKL, Wong WHS, Ma E, et al. Use of midazolam and ketamine as sedation for children undergoing minor operative procedures. *Support Care Cancer*. 2005;13(12):1001–9.
44. Green S, Krauss B. Pulmonary Aspiration Risk during Emergency - an examination of the role of fasting and sedation depth. 2002;9(1):35–42.
45. Hart LS, Berns SD, Houck CS, Boenning D a. The value of end-tidal CO2 monitoring when comparing three methods of conscious sedation for children undergoing painful procedures in the emergency department. *Pediatr Emerg Care*. 1997;13(3):189–93.
46. Kim G, Green SM, Denmark TK. Ventilatory Response during Dissociative Sedation in Children — A Pilot Study. *Acad Emerg Med*. 2003 Feb;10(2):140-5.
47. Karapinar B, Yilmaz D, Demirağ K, Kantar M. Sedation with intravenous ketamine and midazolam for painful procedures in children. *Pediatr Int*. 2006;48(2):146–51.

48. Mandt MJ, Roback MG, Bajaj L, Galinkin JL, Gao D, Wathen JE. Etomidate for short pediatric procedures in the emergency department. *Pediatr Emerg Care*. 2012;28(9):898–904.
49. McQuillen K, Steele D. Capnography during sedation / analgesia in the pediatric emergency department. *Pediatr Emerg Care*. 2000 Dec;16(6):401-4.
50. Miner JR. Randomized Clinical Trial of Propofol versus Methohexital for Procedural Sedation during Fracture and Dislocation Reduction in the Emergency Department. *Acad Emerg Med*. 2003;10(9):931–937.
51. Miner JR, Biros MH, Seigel T, Ross K. The utility of the bispectral index in procedural sedation with propofol in the emergency department. *Acad Emerg Med*. 2005;12(3):190–6.
52. Miner JR, Martel ML, Meyer M, Reardon R, Biros MH. Procedural sedation of critically ill patients in the emergency department. *Acad Emerg Med*. 2005;12(2):124–8.
53. Miner JR, Huber D, Nichols S, Biros M. The effect of the assignment of a pre-sedation target level on procedural sedation using propofol. *J Emerg Med*. 2007;32(3):249–55.
54. Miner JR, Danahy M, Moch A, Biros M. Randomized clinical trial of etomidate versus propofol for procedural sedation in the emergency department. *Ann Emerg Med*. 2007;49(1):15–22.
55. Miner JR, Gray RO, Stephens D, Biros MH. Randomized clinical trial of propofol with and without alfentanil for deep procedural sedation in the emergency department. *Acad Emerg Med*. 2009;16(9):825–34.
56. Miner JR, Gray RO, Bahr J, Patel R, McGill JW. Randomized clinical trial of propofol versus ketamine for procedural sedation in the emergency department. *Acad Emerg Med*. 2010;17(6):604–11.
57. Miner JR, Moore JC, Plummer D, Gray RO, Patel S, Ho JD. Randomized clinical trial of the effect of supplemental opioids in procedural sedation with propofol on serum catecholamines. *Acad Emerg Med*. 2013;20(4):330–7.
58. Rahman NHNA, Hashim A. Is it safe to use propofol in the emergency department? A randomized controlled trial to compare propofol and midazolam. *Int J Emerg Med*. 2010;3(2):105–13.
59. Rahman NHN a, Hashim A. The use of propofol for procedural sedation and analgesia in the emergency department: a comparison with midazolam. *Emerg Med J*. 2011;28(10):861–5.
60. Padmanabhan P, Berkenbosch JW, Lorenz D, Pierce MC. Evaluation of cerebral oxygenation during procedural sedation in children using near infrared spectroscopy. *Ann Emerg Med*. 2009;54(2):205–13.
61. Soleimanpour H, Taghizadieh A, Niafar M, Rahmani F, Golzari SE, Esfanjani RM. Predictive value of capnography for suspected diabetic ketoacidosis in the emergency department. *West J Emerg Med*. 2013;14(6):590–4.
62. Soto RG, Fu ES, Vila H, Miguel R V. Capnography accurately detects apnea during monitored anesthesia care. *Anesth Analg*. 2004;99(2):379–82.

63. Van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ. Capnography during deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg*. 2014;119(1):49–55.
64. Weaver CS, Hauter WE, Brizendine EJ, Cordell WH. Emergency department procedural sedation with propofol: is it safe? *J Emerg Med*. 2007;33(4):355–61.
65. Wright SW. Conscious sedation in the emergency department: the value of capnography and pulse oximetry. *Ann Emerg Med*. 1992;21(5):551–5.
66. Willman EV, Andolfatto G. A prospective evaluation of “ketofol” (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. *Ann Emerg Med*. 2007;49(1):23–30.
67. Yildzdaş D, Yapcoglu H, Yilmaz H. The Value of Capnography During Sedation or sedation/analgesia in pediatric minor procedures. *Pediatr Emerg Care*. 2004 Mar;20(3):162-5.